Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 19/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 16/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 11/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.38 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12384703 | 0.89 | OPRL1 (0.42) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL15014587 | 0.80 | KDM2B (0.37) | KDM2B | |
| SCHEMBL23589017 | 0.77 | HRH3 (0.33) | KDM2B | |
| SCHEMBL24854194 | 0.77 | HRH3 (0.33) | KDM2B | |
| SCHEMBL17285903 | 0.77 | ALDH1A1 (0.41) | KDM2B | |
| SCHEMBL20096182 | 0.76 | KDM2B (0.42) | OPRL1OPRM1OPRK1OPRD1KDM2B | |
| SCHEMBL20095966 | 0.76 | KDM2B (0.42) | OPRL1OPRM1OPRK1OPRD1KDM2B | |
| SCHEMBL20095968 | 0.76 | KDM2B (0.42) | OPRL1OPRM1OPRK1OPRD1KDM2B | |
| SCHEMBL10216734 | 0.74 | OPRL1 (0.44) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL23588931 | 0.74 | L3MBTL3 (0.33) | KDM2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461328-B2 | Tricyclic heterocyclic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CCNY, CCNA1, CCNA2 | OPRL1 3542/4885OPRM1 3594/4885OPRK1 2237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.